Background: The combination of increased cardiovascular mortality and vascular complications due to dyslipidaemia in chronic kidney disease (CKD) has focused attention onto the potential beneficial effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA) inhibitors (statins) on the course of CKD.
Objective: To examine the use of statins in CKD.
Methods: A review of relevant literature.
Results/conclusion: Current evidence from clinical trials in CKD patients on maintenance dialysis is limited. Therefore, the routine use of statins in this population remains the decision of individual physicians in discussion with their patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1517/14728220902882130 | DOI Listing |
Publication Analysis
Top Keywords
nephroprotective clinical
4
clinical potential
4
statins
4
potential statins
4
statins dialyzed
4
dialyzed patients
4
patients background
4
background combination
4
combination increased
4
increased cardiovascular
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!